February 27, 2020 02:50 PM IST The licensing pact for Ryaltris has been signed between the company's Swiss subsidiary, Glenmark Specialty SA and Hikma Pharmaceuticals PLC (Hikma).
February 14, 2020 09:16 PM IST The company had posted a net profit of Rs 116.34 crore in the corresponding period of the previous financial year, Glenmark Pharmaceuticals said in a filing to the BSE.
February 11, 2020 07:26 PM IST The Mumbai-based firm plans to raise funds either through issuance of bonds or debentures, non-convertible debt instruments or any other securities or any combination thereof, of any of the above, it added.
December 23, 2019 01:59 PM IST "This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment," Mankind Pharma Director of Marketing Sanjay Koul said in a statement.
December 20, 2019 11:08 AM IST Ryaltris is a new fixed dose combination nasal spray of an antihistamine and a steroid indicated for treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients over 12 years of age in Australia.
December 16, 2019 10:45 AM IST "The European regulator has just issued a certificate of compliance for the facility stating that it complies with the principles and guidelines of Good Manufacturing Practice (GMP) laid down in the directive 2003/94/EC which stipulates the requirements to fulfil GMP recommendations of WHO," Glenmark Pharmaceuticals said in a regulatory filing.
November 26, 2019 11:10 AM IST Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA.
November 14, 2019 08:56 PM IST Net sales of the company stood at Rs 2,763.73 crore, up 8.81 percent, during the period under review as against Rs 2,539.85 crore of the corresponding quarter previous fiscal.
October 07, 2019 08:38 AM IST Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 17 points gain or 0.16 percent. The Nifty futures were trading around 11,223-level on the Singaporean Exchange.
September 03, 2019 09:06 PM IST In his message to the company's shareholders, Saldanha said the three entities will focus on different verticals -- generics, branded and specialty products; active pharmaceutical ingredients (API); and breakthrough innovative drugs.
August 25, 2019 12:28 PM IST The recall is a nationwide within the United States, the USFDA said.
August 19, 2019 02:40 PM IST The drug is indicated for treatment of type-2 diabetes mellitus in adults.
August 16, 2019 03:19 PM IST ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 410 in its research report dated August 14, 2019.
August 13, 2019 08:49 PM IST The Mumbai-based drug firm said the figures are not comparable as the last financial year included one-time forex gain of Rs 138.21 crore.
July 11, 2019 11:07 AM IST The company, however, did not disclose financial details of the licensing agreement.
July 11, 2019 10:42 AM IST Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India.
July 09, 2019 02:18 PM IST Ranolazine is used to treat chronic angina.
July 09, 2019 12:07 PM IST Glenmark's current portfolio consists of 158 products authorised for distribution in the US marketplace and 57 ANDA’s pending approval with the USFDA
June 22, 2019 03:27 PM IST The company said it will continue to pursue regulatory approval for Ryaltris and work closely with the FDA to determine the appropriate next steps.
June 18, 2019 12:03 PM IST ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 565 in its research report dated May 30, 2019.
June 03, 2019 04:43 PM IST Sharekhan recommended Hold rating on Glenmark Pharmaceuticals with a target price of Rs 595 in its research report dated May 30, 2019.
May 29, 2019 10:45 PM IST The company's consolidated revenue for 2018-19 stood at Rs 9,865.46 crore, compared to Rs 9,103.07 crore in the preceding fiscal.
May 14, 2019 10:50 AM IST The approved products is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.
May 07, 2019 11:12 AM IST Rawjee joins Glenmark Life Sciences from Mylan, where most recently he was the Head of Global API Operations.
April 12, 2019 01:11 PM IST Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.
